{"id":"ct-p42","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Decreased appetite"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Immune-related adverse events (pneumonitis, hepatitis, colitis)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"CT-P42 is a PD-L1 checkpoint inhibitor developed as a biosimilar candidate to atezolizumab. By blocking the PD-L1/PD-1 axis, it prevents tumor cells from suppressing T-cell mediated immunity, thereby reactivating the body's anti-tumor immune response. This mechanism is used across multiple cancer types where PD-L1 expression is associated with immune evasion.","oneSentence":"CT-P42 is a monoclonal antibody that binds to and inhibits programmed death ligand 1 (PD-L1), blocking its interaction with PD-1 and restoring anti-tumor immune responses.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:08:01.115Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"},{"name":"Urothelial carcinoma"},{"name":"Triple-negative breast cancer"}]},"trialDetails":[{"nctId":"NCT04739306","phase":"PHASE3","title":"Study to Compare Efficacy and Safety of CT-P42 in Comparison With Eylea in Patients With Diabetic Macular Edema","status":"COMPLETED","sponsor":"Celltrion","startDate":"2021-07-22","conditions":"Diabetic Macular Edema (DME)","enrollment":348}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"CT-P42","genericName":"CT-P42","companyName":"Celltrion","companyId":"celltrion","modality":"Biologic","firstApprovalDate":"","aiSummary":"CT-P42 is a monoclonal antibody that binds to and inhibits programmed death ligand 1 (PD-L1), blocking its interaction with PD-1 and restoring anti-tumor immune responses. Used for Non-small cell lung cancer, Urothelial carcinoma, Triple-negative breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}